Dr. Shireen Vali Co-Founder

Shireen has dedicated the last decade of her life to a detailed understanding of the biology of cancer, auto-immune, dermatology and infectious disease. As Co-founder and Chief Scientific Officer of Cellworks Group, Dr. Shireen Vali has been instrumental in building the Cellworks R&D organization spanning multiple disease indications from initiation to size of over 125. Under her leadership Cellworks’ in-vivo equivalent technology representing disease physiology has grown to over a million signaling and metabolic cross talk interactions.

Dr. Shireen Vali also oversees the development pipeline of therapeutic programs for cancer, ensuring Cellworks stays at the forefront of innovation and therapy.

She brings over two decades of experience in molecular and cellular biology research and development to the company. Dr. Shireen Vali holds a PhD, Neuroscience from U.C. Davis and has completed her fellowship at Stanford University. She has co-authored and presented tens of articles in scientific publications and industry conferences worldwide.

Taher Abbasi Co-Founder

Taher has been instrumental in building Cellworks into a world leader in personalized therapy. As Co-founder & COO, Taher Abbasi has been part of the core team involved in establishing the Cellworks R&D operations and processes, global research collaborations and developing strategy for implementing Cellworks proprietary technology automation infrastructure to emulate disease physiology computationally and designing therapeutics pipeline. He has over twenty years of technology and global operations setup and management experience. His specialization is automation engineering in the semiconductor and life sciences therapeutics industries.

Prior to co-founding Cellworks Group Inc., Taher Abbasi held senior management positions in Cadence Design Systems, Get2Chip, Vitalect and Synopsys. Taher Abbasi is the co-author of the books “Logic Synthesis Using Synopsys” (Kluwer publication) and “It’s the Methodology, Stupid!” (ByteK publication). He has co-authored and presented several articles in scientific publications and industry conferences worldwide.

He holds a B.S. in Electronics from University of Bombay; M.S. in Computer Engineering from California State University, Northridge; MBA from University of California, Los Angeles and National University of Singapore.


Cellworks is a life sciences technology company that improves clinical outcomes and creates value for pharma, payors and physicians. Cellworks does this through computational modeling, simulation and annotation of tumor genomics for clinical therapeutics predictions.

Cellworks can

  • Identify patients who will respond or not respond to a specific treatment
  • Design patient specific cocktails of existing FDA approved agents for unmet treatment needs
  • Identify predictor bio-marker signatures (companion diagnostics) for a drug agent to target clinical trials to the right patients
  • Identify novel target indications for a drug – for drug rescue and repositioning

Yatin Mundkur Partner, Artiman

View Profile 




Infectious diseases

Building Precision Cancer Therapeutics